X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs MERCK LTD - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER MERCK LTD PFIZER/
MERCK LTD
 
P/E (TTM) x 35.3 48.0 73.5% View Chart
P/BV x 5.8 7.2 79.4% View Chart
Dividend Yield % 0.7 0.4 168.3%  

Financials

 PFIZER   MERCK LTD
EQUITY SHARE DATA
    PFIZER
Mar-17
MERCK LTD
Dec-16
PFIZER/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs2,0551,060 193.9%   
Low Rs1,651623 265.0%   
Sales per share (Unadj.) Rs429.8632.4 68.0%  
Earnings per share (Unadj.) Rs73.645.7 161.0%  
Cash flow per share (Unadj.) Rs87.462.3 140.2%  
Dividends per share (Unadj.) Rs20.0011.00 181.8%  
Dividend yield (eoy) %1.11.3 82.6%  
Book value per share (Unadj.) Rs528.7388.8 136.0%  
Shares outstanding (eoy) m45.7516.60 275.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.31.3 324.0%   
Avg P/E ratio x25.218.4 136.8%  
P/CF ratio (eoy) x21.213.5 157.1%  
Price / Book Value ratio x3.52.2 161.9%  
Dividend payout %27.224.1 112.9%   
Avg Mkt Cap Rs m84,77713,969 606.9%   
No. of employees `0002.81.6 179.3%   
Total wages/salary Rs m3,0391,487 204.4%   
Avg. sales/employee Rs Th6,925.96,631.9 104.4%   
Avg. wages/employee Rs Th1,070.4939.2 114.0%   
Avg. net profit/employee Rs Th1,186.3479.4 247.4%   
INCOME DATA
Net Sales Rs m19,66310,498 187.3%  
Other income Rs m1,012242 417.3%   
Total revenues Rs m20,67410,741 192.5%   
Gross profit Rs m3,4911,135 307.5%  
Depreciation Rs m629276 228.4%   
Interest Rs m100-   
Profit before tax Rs m3,8641,102 350.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,3040-   
Tax Rs m1,801343 524.5%   
Profit after tax Rs m3,368759 443.8%  
Gross profit margin %17.810.8 164.2%  
Effective tax rate %46.631.1 149.6%   
Net profit margin %17.17.2 236.9%  
BALANCE SHEET DATA
Current assets Rs m20,7896,410 324.3%   
Current liabilities Rs m7,8708,828 89.1%   
Net working cap to sales %65.7-23.0 -285.2%  
Current ratio x2.60.7 363.9%  
Inventory Days Days6058 103.6%  
Debtors Days Days2238 58.4%  
Net fixed assets Rs m9,1751,406 652.4%   
Share capital Rs m458166 275.6%   
"Free" reserves Rs m23,7316,286 377.5%   
Net worth Rs m24,1896,455 374.8%   
Long term debt Rs m250-   
Total assets Rs m32,7068,828 370.5%  
Interest coverage x403.5NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.61.2 50.6%   
Return on assets %10.38.6 120.1%  
Return on equity %13.911.8 118.4%  
Return on capital %21.417.1 125.2%  
Exports to sales %08.3 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA869 0.0%   
Imports (cif) Rs mNA2,209 0.0%   
Fx inflow Rs m63959 6.6%   
Fx outflow Rs m4,0672,612 155.7%   
Net fx Rs m-4,004-1,653 242.2%   
CASH FLOW
From Operations Rs m3,2881,070 307.2%  
From Investments Rs m-2,496-750 333.0%  
From Financial Activity Rs m-826-150 551.3%  
Net Cashflow Rs m-35171 -20.2%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 63.9 51.8 123.4%  
Indian inst/Mut Fund % 7.5 18.2 41.2%  
FIIs % 4.9 1.0 490.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 29.1 81.4%  
Shareholders   85,207 28,591 298.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   STERLING BIOTECH  NOVARTIS  DR. DATSONS LABS  SHASUN PHARMA  GSK PHARMA  

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trims Losses; Rupee Devalues to Record Low(12:30 pm)

Stock markets in India trim losses to turn flat even as rupee fell 43 paise to hit record low of 70.29 against the US dollar.

Related Views on News

PFIZER at All Time High; BSE HEALTHCARE Index Up 0.9% (Market Updates)

Aug 16, 2018 | Updated on Aug 16, 2018

PFIZER share price has hit an all time high at Rs 3,056 (up 4.6%). The BSE HEALTHCARE Index is up by 0.9%. Among the top gainers in the BSE HEALTHCARE Index today are PFIZER (up 4.6%) and ABBOTT INDIA (up 0.2%). The top losers include NATCO PHARMA (down 0.1%) and CAPLIN POINT (down 0.1%).

PFIZER at All Time High; BSE HEALTHCARE Index Up 1.1% (Market Updates)

Aug 16, 2018 | Updated on Aug 16, 2018

PFIZER share price has hit an all time high at Rs 3,018 (up 4.0%). The BSE HEALTHCARE Index is up by 1.1%. Among the top gainers in the BSE HEALTHCARE Index today are PFIZER (up 4.0%) and SANOFI INDIA (up 0.8%). The top losers include ALKEM LABORATORIES (down 0.1%) and ABBOTT INDIA (down 0.2%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Aug 16, 2018 03:03 PM

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS